- Myeloproliferative Neoplasms (MPN)
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)
Hematopoietic cell transplantation and cell-based immunotherapies of malignant blood disorders and solid tumors.
- Gene therapy
- Cell therapy
- Immunotherapy
- CAR-T cells
- Conduct of the first and only phase I clinical study evaluating a somatic cell therapy drug candidate composed of allogeneic NK cells activated in vitro as post-allograft immunotherapy (Devillier R, et al., Cancers (Basel). 2021 May 28;13 (11):2673.)
- Key role in the installation (“onboarding”) of authorized and marketed autologous CAR-T Cell drug circuits allowing access to these treatments for patients in the PACA West and PACA East regions; construction at the IPC and AP-HM of a portfolio of early clinical trials evaluating innovative CAR-T cells or new indications for CAR-T Cells already authorized
- Installation of medical biology techniques necessary for clinical and real-time biological monitoring of CAR-T Cells
- The investigators of the CTC and the Biotherapies module
- were at the origin of the European registry of CAR-T Cells and post-marketing authorization (MA) monitoring studies carried out on a European scale with authorized CAR-T cells
- are important and regular contributors to the publication of guidelines for the management of patients candidates for treatment with CAR-T Cells
- are at the origin of numerous training actions intended for different categories of professionals in this rapidly emerging field, for example the series of European EBMT – EHS congresses on CAR-T Cells
- Development of conditions allowing the delocalized production of autologous CAR-T Cells, to cover orphan indications or evaluate innovative CAR-T cells
- Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, Ruggeri A, Fleischhauer K, Bonini C. Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Sci Transl Med. 2018 Apr 11;10(436). pii: eaap9630. doi: 10.1126/scitranslmed.aap9630. Review. PMID: 29643233.
- Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, Ruggeri A, Secondino S, Bonini C, Pedrazzoli P. Development of adaptive immune effector therapies in solid tumors. Ann Oncol. 2019 Nov;30(11):1740-1750. doi: 10.1093/annonc/mdz285. Epub 2020 Jan 8. Review. PMID: 31435646 Review.
- Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N. Management of adults and children undergoing CAR T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2019 Nov 21. pii: haematol.2019.229781. doi: 10.3324/haematol.2019.229781. [Epub ahead of print]. PMID: 31753925.
- Wensing AMJ, Chabannon C, Kuball J. The connected worlds of stem cell transplantation and HIV. Lancet HIV. 2020 Sep;7(9):e594-e595. doi: 10.1016/S2352-3018(20)30170-3. Epub 2020 Jul 7. No abstract available. PMID: 32649867.
- McGrath E, Chabannon C, Terwel S, Bonini C, Kuball J. Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. Curr Opin Oncol. 2020 Sep;32(5):427-433. doi: 10.1097/CCO.0000000000000665. PMID: 32665456 Review.
- Devillier R, Calmels B, Guia S, Taha M, Fauriat C, Mfarrej B, Venton G, Vivier E, Olive D, Chabannon C, Blaise D, Ugolini S. Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. Cancers (Basel). 2021 May 28;13(11):2673. doi: 10.3390/cancers13112673. PMID: 34071607.
- Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, Sauer MG, Thuret I, Lal A, Algeri M, Schneiderman J, Olson TS, Carpenter B, Amrolia PJ, Anurathapan U, Schambach A, Chabannon C, Schmidt M, Labik I, Elliot H, Guo R, Asmal M, Colvin RA, Walters MC. Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia. N Engl J Med. 2022 Feb 3;386(5):415-427. doi: 10.1056/NEJMoa2113206. Epub 2021 Dec 11. PMID: 34891223.
- Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, Mohty M, Neven B, Peffault de Latour R, Peri? Z, Snowden JA, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplant. 2022 May;57(5):742-752. doi: 10.1038/s41409-022-01604-x. Epub 2022 Feb 22. PMID: 35194156.
- Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16. Online ahead of print. PMID: 34923107.
- Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022 Aug;57(8):1217-1239. doi: 10.1038/s41409-022-01691-w. Epub 2022 May 19. PMID: 35589997.
- Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jaeger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sanchez-Guijo FM, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden J, Thieblemont C, Topp MS, Zinzani PL, Gribben JG, Bonini C, Sureda Balari A, Yakoub-Agha I. Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations. Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578. PMID: 37300386.
